Core Viewpoint The article discusses the financial practices and market position of Yuwang Biological Nutrition Co., Ltd., highlighting concerns over its recent dividend distribution and the implications for its upcoming IPO. Industry Overview - The global nutritional supplement industry is rapidly growing, with fish oil being a significant segment due to its health benefits across all age groups [2][44]. - Fish oil is rich in Omega-3 fatty acids, which help reduce cardiovascular risks in the elderly and have potential benefits for brain health [2][44]. - The global market for human-grade fish oil is expected to grow at a compound annual growth rate (CAGR) of 8.89%, reaching $990 million by 2029 [2][44]. Company Overview - Yuwang Biological has submitted an IPO application to the Hong Kong Stock Exchange, citing several funding needs for expansion and operations [5][6]. - The company distributed a significant dividend of 320 million yuan just before filing for the IPO, which is equivalent to its total profit over the past three and a half years [7][11]. - The company has a high debt ratio exceeding 80%, with cash reserves insufficient to cover the recent dividend payout [12][15]. Financial Performance - Yuwang Biological reported a revenue increase from 534 million yuan in 2022 to 832 million yuan in 2024, with a CAGR of 24.8% [22][62]. - However, in the first half of 2025, the company experienced a 27% decline in revenue to 343 million yuan and a 74% drop in profit to 23 million yuan [24][64]. - The gross margin fell to 20.74% in the first half of 2025, a nearly 9 percentage point decrease from the previous year [25][65]. Market Position - Yuwang Biological claims to be the largest supplier of food-grade refined fish oil, holding an 8.12% market share [18][58]. - The overall market concentration is low, with the top five companies holding only 32.37% of the market, indicating intense competition [18][58]. - The global fish oil market is currently valued at just over $800 million, with limited growth potential [21][61]. Challenges - The company faces significant challenges due to high raw material costs and price volatility, as fish oil prices have fluctuated dramatically [27][71]. - Yuwang Biological's reliance on fish oil for over 98% of its revenue makes it vulnerable to supply chain disruptions and price increases [67][72]. - The company has seen a substantial loss of customers, with domestic clients decreasing from 310 to 190 and international clients from 240 to 190 in the first half of 2025 [36][76]. Brand and Sales Strategy - Yuwang Biological has shifted focus from building its own brand to acting as an OEM for international dietary supplement brands, with over 60% of revenue coming from overseas [34][74]. - The company has increased marketing expenditures but has seen limited success in building its consumer brand, with only 2.1% of total revenue coming from direct consumer sales [38][78].

Core Viewpoint - The article discusses the questionable financial practices of Yuwang Biological Nutrition Co., Ltd., particularly focusing on a significant dividend payout that appears to deplete the company's profits just before its IPO application, raising concerns about its financial health and sustainability [7][8][14]. Industry Overview - The global nutritional supplement industry, particularly the fish oil segment, is experiencing rapid growth due to increasing health awareness, with the market expected to reach $990 million by 2029, growing at a compound annual growth rate (CAGR) of 8.89% from 2025 to 2029 [4]. - Fish oil is recognized for its health benefits across various age groups, including cardiovascular risk reduction and cognitive support [3]. Company Financial Practices - Yuwang Biological's pre-IPO actions included a substantial dividend payout of 320 million yuan, which effectively drained the company's profits from the past three and a half years, totaling only 294 million yuan [8][11][14]. - The company has a high debt-to-asset ratio exceeding 80%, and as of the end of 2023, it had only 53.29 million yuan in cash, insufficient to cover the dividend payout [16][18]. - By the end of 2024, the company still had 122 million yuan in unpaid dividends, indicating a troubling financial situation [17]. Business Performance - Yuwang Biological claims to be the largest supplier of food-grade refined fish oil, with a market share of 8.12% in 2024, but the industry is characterized by low concentration and intense competition [21][23]. - The company's revenue grew from 534 million yuan in 2022 to 832 million yuan in 2024, but it faced a dramatic decline in the first half of 2025, with revenue dropping 27% year-on-year to 343 million yuan and profits plummeting 74% to 23 million yuan [25][27]. - The company's gross margin fell to 20.74% in the first half of 2025, a nearly 9 percentage point decrease from the previous year, primarily due to rising raw material costs and fluctuating sales [28]. Market Challenges - The fish oil market is limited, with a total market size of just over 8 billion yuan, and the competition is fierce, with the top five companies holding only a 32.37% market share [24][23]. - Yuwang Biological's reliance on fish oil, which accounts for over 98% of its revenue, exposes it to risks from raw material price volatility and supply chain issues [32]. - The company has faced significant customer attrition, with domestic clients decreasing from 310 to 190 and international clients dropping from 240 to 190 in the first half of 2025 [45]. Brand and Sales Strategy - Yuwang Biological initially focused on building its own brand but has shifted towards OEM production for international dietary supplement brands, with over 60% of its revenue coming from overseas by 2024 [40]. - The company has struggled to establish a strong brand presence, with consumer sales accounting for only 2.1% of total revenue in 2024, despite increased marketing expenditures [44][43].